ESTRO 2024 - Abstract Book

S1910

Clinical - Mixed sites, palliation

ESTRO 2024

Median follow up was 20.8 months (range 2.2-92.4).

27 patients (65.8%) started or changed systemic therapy due to disease progression during follow up. Median TTNS was 12.8 months (95% CI 8,030-18,370). TTNS free survival at 1 and 2 years was 53% ± 7.9% and 25.2% ± 7.2%, respectively. At last follow up, 21 (51.2%) patients died all but one due to neoplastic disease. Four patients (9.7%) were free of disease (13.7%), while the rest of the patients were alive but with metastatic disease. Median OS was 37.1 months (95% CI 27,130-44,670). OS at 1 and 2 years was 87.3% ± 5.3% and 77.2% ± 7.6%, respectively. Four patients had a local recurrence (9.7%), all relapsed also in distant sites. Generally, 36 patients (87.8%) relapsed outside of RT field, 23 in the pleura, three in pleural and extrapleural sites, while the remnant 10 patients relapsed in other organs. At progression, 3 patients were candidate to best supportive care, 11 were managed with further RT, two with both RT and systemic therapy and 20 with a new line of systemic therapy. Median local control was not reached. LC at 1 and 2 years was 97.5% ± 2.5% and 93.8% ± 4.4%, respectively.

Median PFS was 7.9 months (95% CI 4,270 to 9,970). PFS at 1 and 2 years was 31.6% ± 7.5% and 7% ± 4.4%, respectively.

Conclusion:

SABR is a safe and effective approach for the treatment of oligorecurrent/oligoprogressive PM, although cronic thoracic pain is reported by 10% of patients. Time to new systemic therapy is prolonged up to 12 months. Ten percent of patients are free from disease at 2 years and more than half are alive at 3 years, suggesting a possible indolent biology of oligometastatic PM.

Keywords: Pleural Mesotelioma, Stereotactic Radiotherapy

1318

Digital Poster

Long-term Outcome of Interstitial Alpha Radionuclide Treatment for Skin and Head and Neck Cancers

Aron Popovtzer 1 , Aviram Mizrachi 2 , Mark A D'Andrea 3 , Noam A VanderWalde 4 , Noga Kurman 2 , Eli Rosenfeld 5 , Ran Ben-Hur 6 , Giacomo Feliciani 7 , Salvatore Roberto Bellia 8 , David Silvern 9 , Anna Sarnelli 7 , Matthew T Ballo 4 , Pradeep Patra 10 , Gil'ad N Cohen 11 , Antonio L Damato 11 , Yotam Shkedy 12 , Robert B Den 13 , Christopher A Barker 14 , Tomer Charas 15 , Nir Hirshoren 16 1 Hadassah Medical Center, Sharett Institute of Oncology, Jerusalem, Israel. 2 Rabin Medical Center, Otolaryngology, Petach Tiqva, Israel. 3 University Cancer Centers, Radiation Oncology, Houston, USA. 4 West Cancer Center, Radiation Oncology, Germantown, USA. 5 Rabin Medical Center, Oral &. Maxillofacial Surgery, Petach Tiqva, Israel. 6 Rabin Medical Center, Radiation Safety, Petach Tiqva, Israel. 7 Instituto Scientifico Romagnolo per Lo Studio e la Cura dei Tumori, Medical Physics, Meldola, Italy. 8 Instituto Scientifico Romagnolo per Lo Studio e la Cura dei Tumori,